Skip to Main Content

Paper Details

Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
Eur Urol
34
2020
Advanced Prostate Cancer, Androgen, CVD, CVDs, Cardiovascular Comorbidities, ENZ, Men, PARTICIPANTS, PATIENT, Patients, abiraterone acetate, advanced prostate cancer, cardiovascular disease, cardiovascular diseases, enzalutamide, patients, prostate cancer
Author NameAffiliation
Timothy R RebbeckDana Farber Cancer Institute and Harvard TH Chan School of Public Health
Philip W KantoffMemorial Sloan Kettering Cancer Center
Philip W KantoffMemorial Sloan Kettering Cancer Center
  • 1 - 3

Datasets

Release 1.2